Inclusion Criteria:  Must be willing to participate in the study and provide written informed consent Male or female patients ≥ 18 and < 75 years Centrally assessed histological evidence of NASH and liver fibrosis Women of childbearing potential agree to use a highly effective method of birth control during the entire duration of the trial and for 4 weeks following the last dose of trial treatment  Exclusion Criteria:  Patients taking prohibited medications Presence of liver cirrhosis Type 1 diabetes or uncontrolled Type 2 diabetes History or presence of any other significant concomitant liver diseases History of liver transplantation BMI >45 kg/m^2 Any known relevant infectious disease (e.g., active tuberculosis, acquired immunodeficiency syndrome [AIDS]-defining diseases) Abnormal renal function (glomerular filtration rate estimated from cystatin C < 30 ml/min) at screening visit Any active malignant disease (except for basal cell carcinoma) Existing or intended pregnancy or breast-feeding